FogPharma raises $145 million in rare Series E round

FogPharma, an oncology startup based in Cambridge, Mass., recently closed a $145 million Series E round of financing. The company is developing cancer treatments using unique peptides called helicons that could potentially improve cell penetration. CEO Mathai Mammen believes that many drugs released by pharma and biotech companies are only incrementally better than existing treatments,…

Read More

Antibiotic costs rise 1100% as big pharma exits Nigeria

Yemisi Bokinni, a freelance journalist in London, reports on the economic struggles facing Nigeria due to the departure of major drug companies. This has led to a 1100% increase in antibiotic costs and other healthcare prices in the country. The escalating drug prices reflect a larger issue with Nigeria’s economy, with inflation reaching a 27-year…

Read More

California hospitals, advocates seek stable funding to retain behavioral health navigators

Health providers and addiction experts are concerned about the unstable funding structure of California’s CA Bridge initiative, which aims to place patients with substance use disorder into long-term treatment after they leave the emergency room. The program, which relies on one-time funding, has led to employees leaving critical positions. Despite the program’s success in prescribing…

Read More

Exercise Tips for Overweight Kids

Motivating a child to exercise can be challenging if they aren’t interested, but there are ways to inspire them. Dr. Blaise A. Nemeth suggests exercising with your child in a fun way, talking about the benefits of physical activity, and finding creative ways to get them moving without them realizing. Understanding why your child may…

Read More

Alzheimer’s Biomarker Changes 20 Years Before Diagnosis

A 20-year study tracked biomarker changes in adults progressing from normal cognition to sporadic Alzheimer’s disease (AD), using cerebral spinal fluid (CSF) analysis, cognitive assessments, and brain imaging. Changes in levels of Aβ42, p-tau181, and NfL were observed years before clinical symptoms appeared, with accelerated changes followed by a slowing of progression up to diagnosis….

Read More
error: Content is protected !!